ArticleCancer medicine2025
Breast Cancer Survivors' Perceptions of Their Cardiovascular Care During Treatment With Anthracyclines or Trastuzumab: A Qualitative Analysis.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCardiovascular disease (CVD) is a leading cause of mortality among breast cancer survivors, and racial disparities exist between Black and White women. Therefore, the purpose of this study was to assess breast cancer survivors' perceptions of heart health resources and communication received during active treatment with potentially cardiotoxic therapies and to evaluate whether differences in perceptions are associated with race.
methodsThis qualitative analysis included semi-structured interviews with breast cancer survivors who received potentially cardiotoxic treatment(s). Survivors were asked to recall conversations with their healthcare providers regarding cancer treatment, the risk of CVD during and following treatment, and discussions of heart healthy behaviors that could be employed during treatment. Audio recorded interviews were transcribed, and codes were developed using Dedoose Qualitative Software.
resultsOf the 17 participants, 9 women were White and 8 were Black. A majority of participants were married (58.8%), reported an annual household income of at least $60,000, had a Bachelor's degree or higher (70.6%), and had a mastectomy (70.6%). Participants had an average age of 50.9 years (SD = 11.85). Approximately 88% (100% White women, 75% Black women) recalled receiving heart health information either prior to or during treatment. The majority also received trastuzumab (88.2%). Four themes were identified from the interviews. Key results showed that Black survivors were more likely to share positive experiences when their family members were a part of their treatment conversations and that White women were more likely to have positive experiences throughout their treatment.
conclusionsThis qualitative analysis did not show striking differences in perceived care experiences between Black and White survivors. However, there were notable differences in community support, such as the inclusion of family members in treatment conversations and the receipt and timing of heart health information. Enhancing healthcare communication with a particular focus on culturally diverse populations is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.